Telix Pharmaceuticals Limited (TLX) — Financial statements
Income statement, balance sheet, and cash flow for Telix Pharmaceuticals Limited — annual and quarterly history with growth and margin analysis.
| Metric (AUD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,205↑53.9% | 783↑55.8% | 503↑213.9% | 160↑2007.6% | 8 | |
| Cost of Revenue | 565↑106.6% | 274↑45.4% | 188↑43.9% | 131↑250.0% | 37 | |
| Gross Profit | 640↑25.6% | 510↑62.1% | 314↑971.7% | 29↑198.6% | -30 | |
| Operating Expenses | ||||||
| R&D Expenses | 257↑112.2% | 121↓6.1% | 129↑122.7% | 58↑69.5% | 34 | |
| General & Administrative Expenses | 0.00↓100.0% | 122↑54.0% | 79↑60.8% | 49↑40.7% | 35 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 85↑55.8% | 55↑44.5% | 38↑544.5% | 6 | |
| SG&A Expenses | 357↑72.2% | 207↑54.4% | 134↑54.0% | 87↑85.4% | 47 | |
| Other Expenses | 0.00↓100.0% | 99↑36711.5% | 0.27↑100.6% | -42 | 0.00 | |
| Operating Expenses | 614↑43.5% | 428↑62.4% | 263↑156.8% | 103↑26.4% | 81 | |
| Total Costs & Expenses | 1,179↑68.1% | 701↑55.4% | 451↑79.0% | 252↑183.7% | 89 | |
| Operating Results | ||||||
| Operating Income | 27↓67.6% | 82↑58.3% | 52↑156.4% | -92↓13.1% | -81 | |
| Depreciation & Amortization | 33↑474.5% | 6↓15.7% | 7↑25.4% | 5↑4.0% | 5 | |
| EBITDA | 80↓18.7% | 98↑327.7% | 23↑124.7% | -93↓32.5% | -70 | |
| EBIT | 47↓49.0% | 93↑470.5% | 16↑116.5% | -98↓30.5% | -75 | |
| Interest & Other Income | ||||||
| Net Interest Income | -46↓337.0% | -11↑16.8% | -13↓3046.9% | -0.41↓148.5% | -0.16 | |
| Interest Income | 9↓19.6% | 11↑1464.6% | 0.69↑69324.5% | 0.00↓99.4% | 0.16 | |
| Interest Expense | 55↑156.5% | 21↑58.3% | 14↑3239.4% | 0.41↑114.8% | 0.19 | |
| Non-Operating Income | -21↓97.0% | -10↓129.2% | 36↑300.1% | -18↓197.1% | -6 | |
| Other Income / Expenses | -35↓32.5% | -26 | 0.00↑100.0% | -7↑62.4% | -18 | |
| Income Before Tax | -8↓114.1% | 56↑1715.9% | 3↑103.1% | -99↑0.4% | -99 | |
| Income Tax Expense | 3↓54.6% | 6↑388.9% | -2↓138.9% | 5↑129.5% | -19 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -11↓121.4% | 50↑858.0% | 5↑105.0% | -104↓29.3% | -81 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -11↓121.4% | 50↑858.0% | 5↑105.0% | -104↓29.3% | -81 | |
| Bottom-Line Net Income | -11↓121.4% | 50↑858.0% | 5↑105.0% | -104↓29.3% | -81 | |
| EPS (Basic) | -0.03↓121.1% | 0.15↑820.2% | 0.02↑104.8% | -0.34↓17.2% | -0.29 | |
| EPS (Diluted) | -0.03↓122.6% | 0.14↑769.6% | 0.02↑104.7% | -0.34↓17.2% | -0.29 | |
| Weighted Average Shares | 338↑2.0% | 331↑3.8% | 319↑2.7% | 311↑10.1% | 282 | |
| Weighted Average Diluted Shares | 338↓2.1% | 345↑6.6% | 324↑4.2% | 311↑10.1% | 282 | |
* All figures in Millions of AUD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.